Patent · US Active

Modified influenza virus for monitoring and improving vaccine efficiency

US9499850B2 · kind B2 · utility

0Cited by

4References

12Claims

0Family size

Assignee

St. Jude Children's Research Hospital, Inc. · US

Inventors

Erich Hoffmann · Memphis, US
Aleksandr S. Lipatov · Atlanta, US
Richard J. Webby · Memphis, US
Elena A. Govorkova · Cordova, US
Robert G. Webster · Memphis, US

Key dates

Filing date	Oct 3, 2013
Grant date	Nov 22, 2016
Priority date	—
Expiry date	Dec 23, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG01N2469/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.